School of Pharmacy and Pharmaceutical Sciences 2021-22 Annual Report

SCHOOL OF PHARMACY AND P H ARMACE U T I C A L SC I E N CES 2021-2022 ANNUAL REPORT

2021-2022 ANNUAL REPORT

SCHOOL OF PHARMACY AND PHARMACEUTICAL SCIENCES

Binghamton University’s School of Pharmacy and Pharmaceutical Sciences saw change in the past year, with the transition from Founding Dean Gloria Meredith following her retirement to Dean Kanneboyina Nagaraju, who had been founding chair of the school’s Department of Pharmaceutical Sciences. In addition, construction began on the 18,000-square-foot research and development facility immediately adjacent in fact connected to our pharmacy building. The R&D facility, which will be completed in 2023, will further support our research efforts. Academically, we saw our second class of Doctor of Pharmacy students graduate, and prepared to enroll our first cohort of students in our master and PhD programs in pharmaceutical sciences in fall 2022. Dare we say that we are now firmly established as a destination school for students wishing to pursue graduate degrees in pharmacy and pharmaceutical sciences? Yes, we so dare. This 2021-2020 annual report is a comprehensive look at the research presentations, publications and funding of our faculty, showcasing their achievements as our nation and the world continue to deal with the effects of the COVID-19 pandemic. Know that we remain committed to providing exceptional learning experiences to our students, even as we achieve the highest levels in our research initiatives.

Dean

Kanneboyina Nagaraju

P3 students Alyssa Waibel, left, and Natalie Young work with a team of fellow students in the Skills Lab to develop a patient care plan.

P3 students Haytham Avdel, standing, and Hakam Virk meet with a patient in one of the Skills Lab hospital rooms.

SOPPS Research Presentations 2021-2022 (July 1, 2021 – June 30, 2022)

Karenbeth Bohan, PharmD

Poster Presentation: Bohan KBH , Paterson JM, Chen H, Ray CL, Cornico E. “Effect of occasional, short-duration meditation on well-being and stress in pharmacy students, faculty, and staff.” American Society of Health-System Pharmacy Midyear Meeting. Virtual. Dec. 7, 2021.

Tracy Brooks, PhD

Platform Presentation: Brooks T. “Facilitating G-quadruplex formation in the KRAS promoter with polypurine reverse Hoogsteen oligonucleotides.” American Association of Cancer Research, Transcription Factors in Cancer MiniSymposium Annual Meeting. New Orleans, La. Apr. 10, 2022.

Danielle Cabral, PharmD

Poster Presentation: Cabral D. “An Unusual Presentation of Hereditary Angioedema.” American College of Asthma Allergy and Immunology Annual Scientific Meeting. New Orleans, La. Nov. 2021.

Platform Presentation: Cabral D. “Extinguishing Burnout.” Continuing Education , 1 credit hour. New York State Council of Health-system Pharmacists. Virtual. Dec. 14, 2021.

Platform Presentation: Cabral D. “Renal Refresher: Preventing the progression of chronic kidney disease.” Continuing Education , 1 credit hour. Southern Tier

Chapter of the New York State Council of Health-system Pharmacists. Virtual. Jan. 18, 2022.

Anthony Di Pasqua, PhD

Poster Presentation: Osipitan OO , Gaurkhede SG, Dromgoole G, Spencer S, Deng J, Di Pasqua AJ . “Preparation and dissolution testing of novel 3D printed capsule shells for drug delivery.” 12th Annual Charles I. Jarowski Symposium. Virtual. Sept. 17, 2021.

Poster and Podium Presentation: Sun M , Yuan Y, Psaras A , Brooks T , Lu F, Di Pasqua AJ . “Optimization of biocompatible liposomes for the delivery of mRNA and plasmid DNA in human ovarian SK-OV-3 cells.” 12th Annual Charles I. Jarowski Symposium. Virtual. Sept. 17, 2021. Winner of On-Demand Oral Presentation Award

Bennett Doughty, PharmD

Platform Presentation: Doughty B. “Taking the Anxiety Out of the Psych Consult.” New York State American College of Clinical Pharmacists Annual Meeting. Waterloo, N.Y. Nov. 5, 2021.

Katie Edwards, PhD

Platform Presentation: Edwards KA , Randall EA, Wolfe P , Angert E, Kraft CE. “Elucidating the impact of dietary composition on thiaminase 1-mediated thiamine deficiency.” Joint Aquatic Sciences Meeting. Grand Rapids, Mich. May 16, 2022.

Poster Presentation: Stahura CM, Ernst P, Wolfe P, Edwards KA. “Development of Assay Platforms for Monitoring Biomarkers in Duchenne Muscular Dystrophy.” American Society of Health-System Pharmacy Midyear Meeting. Virtual. Dec. 8, 2021.

William Eggleston, PharmD

Platform Presentation: Eggleston W. “AACT Critical Care Symposium.” North American Congress of Clinical Toxicology. Atlanta, Ga. Oct. 16-18, 2021.

Platform Presentation: Eggleston W. “A Universe Beyond NAC? Updates in Acetaminophen Toxicity.” SUNY Upstate Regional Toxicology Teaching Day. Syracuse, N.Y. Nov. 3, 2021.

Platform Presentation: Eggleston W. “Drug Use Trends.” Pharmacy Society of Rochester. Virtual. Mar. 6, 2022.

Platform Presentation: Eggleston W, Kam B, Doughty B. “Evaluating Public Perceptions of Expanded Access to Naloxone.” American College of Medical Toxicology Annual Scientific Meeting. Virtual. Mar. 11-13, 2022.

Platform Presentation: Eggleston W. “Emerging Trends in Substance Use.” College of Psychiatric and Neurologic Pharmacists Annual Meeting. San Antonio, Tex. Apr. 24-27, 2022.

Yetrib Hathout, PhD

Poster Presentation: Smith HR, Canessa EH, Hathout Y. “A Single Tick Screening for Infectious Pathogens Using Parallel Reaction Monitoring.” American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics. Philadelphia, Pa. Oct. 31 – Nov. 4, 2021.

Poster Presentation: Canessa EH , Goswami MV, Hoffman EP , Bello L, Elena Pegoraro E, Hathout Y . “Targeted mass spectrometry for dual quantification of dystrophin and utrophin in muscle biopsies from Becker’s muscular dystrophy patients.” American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics. Philadelphia, Pa. Oct. 31 – Nov. 4, 2021.

Eric Hoffman, PhD

Platform Presentation: Hoffman EP “A safer steroidal anti-inflammatory: Structural to clinical studies of vamorolone.” Auburn University, Department of Pharmaceutical Sciences seminar and meetings. Virtual. Aug. 31, 2021.

Platform Presentation: Hoffman EP . “Vamorolone in Duchenne Muscular Dystrophy – Implications for Inflammatory Myositis and Other Inflammatory Disease.” National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases Grand Rounds. Virtual. Oct. 29, 2021.

Platform Presentation: Hoffman EP “Vamorolone clinical trials.” Defeat

Duchenne Family Forum, Jesse’s Journey. London, Ontario, Canada. Nov. 5-7, 2021.

Platform Presentation: Hoffman EP . “Return of clinical trial results.” World Duchenne Foundation, Duchenne Patient Academy 2021. Amsterdam, Netherlands. Dec. 3, 2021.

Platform Presentation: Hoffman EP

“Innovation Conversation with Eric Hoffman.” Parent Project Muscular Dystrophy. Virtual. Dec. 17, 2021.

Rachel Klosko, PharmD

Platform Presentation: Klosko RC “Surpassing Statins: Advancements in Lipid Lowering Therapies.” Continuing Education , 1 credit hour. Southern Tier Society of Health-System Pharmacists. Endicott, N.Y. June 21, 2022.

Wesley Kufel, PharmD

Poster Presentation: Kufel WD , Parsels KA, Steele J, Seabury R, Paolino KM, Thomas SJ. “Vancomycin Plus Ceftaroline Salvage Therapy for Persistent MethicillinResistant Staphylococcus aureus bacteremia.” IDWeek. Virtual. Oct. 1, 2021.

Poster Presentation: Maxwell T, Orban JE, Kufel WD , Destache C, Williams KS, Velagapudi M, Bookstaver PB, Tatem L, McCracken JA, Carpenter B, Sharma R. “Comparative Outcomes Among Patients Receiving Varying Daptomycin Dosing Regimens in Hemodialysis.” IDWeek. Virtual. Oct. 1, 2021.

Poster Presentation: Khan A, Kruthiventi SL, Mahapatra R, Sanyal S, Kufel W . “Legionella bozemanii (Fluoribacter bozemanae) Brain Abscess in a Renal Transplant Recipient.” IDWeek. Virtual. Oct. 1, 2021.

Poster Presentation: Kufel W , Blaine B, Avery L. “Pharmacy students’ knowledge and confidence of COVID-19 following an interactive didactic class.” American College of Clinical Pharmacy Annual Meeting. Virtual. Oct. 19, 2021.

Poster Presentation: Rebold N, Morisette T, Lagnf AM, Alosaimy S, Holger D, Barber K, Justo JA, Antosz K, Carlson TJ, Frens JJ, Biagi M, Kufel WD , Moore WJ, Mercuro N, Raux BR, Rybak MJ. “Early Multicenter Experience with Imipenem-CilastatinRelebactam for Multidrug-Resistant GramNegative Infections.” American College of Clinical Pharmacy Annual Meeting. Virtual. Oct. 19, 2021.

Platform Presentation: Kufel WD . “Lyme is Ticking: Updates on Management of Lyme Disease and Other Tick-Borne Diseases.” Continuing Education , 1 credit hour. New York State American College of Clinical Pharmacy Annual Meeting. Waterloo, N.Y. Nov. 12, 2021.

Platform Presentation: Kufel WD , Darko W. “Development and Implementation of a Formal Pharmacy Residency Research Certificate Program.” Continuing Education , 1.5 credit hours. New York State Council of Health-System Pharmacists Annual Meeting. Saratoga Springs, N.Y. Apr. 9, 2022.

Poster Presentation: Holger DJ, Lagnf AM, Alosaimy S, Rebold NS, Morrisette T, Belza AC, Coyne AK, Ghali AE, Veve M, Newlun D, Kufel WD , Stover K, Rybak MJ. “Impact of Early Antifungal Initiation on Clinical Outcomes in Critically Ill Patients with Candidemia.” European Congress of Clinical Microbiology and Infectious Diseases. Lisbon, Portugal. Apr. 24, 2022.

Poster Presentation: Rebold N, Alosaimy S, Holger D, Lucas K, Guo Y, Chang M, Biagsi M, Carlson TJ, Frens JJ, Barber K, Justo JA, Hayes J, Carr A, Kufel WD , Moore WJ, Zeitler K, Morrisette T, Rybak MJ. “Factors Associated with Clinical Success in Treatment with Imipenem-CilastatinRelebactam.” European Congress of Clinical Microbiology and Infectious Diseases. Lisbon, Portugal. Apr. 24, 2022.

Poster Presentation: Alaosaimy S, Molina K, Wrin JE, Langf A, Athens V, Kufel WD , Polisetty R, Cubillos A, Veve M, Simon S, Biagi M, Yost C, Amaya L, Moore JW, Morisette T, Finch NA, Venugopalan V, Davis SL, Truong J, Rybak MJ. “Nephrotoxicity with Vancomycin in Combination with CeftolozaneTazobactam.” European Congress of Clinical Microbiology and Infectious Diseases. Lisbon, Portugal. Apr. 24, 2022.

Poster Presentation: Rebold N, Guo Y, Carlson TJ, Frens JJ, Barber KE, Kufel WD, Justo JA, Antosz K, Biagi M, Moore WJ, Raux BR, Rybak MJ. “Pseudomonas aeruginosa Infections Treated with Imipenem-Cilastatin-Relebactam.” American Society of Microbiology Microbe. Washington, D.C. June 11, 2022.

Platform Presentation: Kufel WD . “Bad Bugs, ‘New’ Drugs: Updates on Antibiotic Treatment Options for Multidrug Resistant Gram-Negative Bacterial Infections.” Continuing Education , 1 credit hour. AchieveCE. Virtual. Aug. 31, 2021.

Emily Leppien, PharmD

Platform Presentation: Leppien E . “The Grass is Greener on the Medical Side.” University of California Davis Pre-Health Conference. Virtual. Oct. 2021.

Platform Presentation: Leppien E “Updates in Migraine Pharmacotherapy.” Continuing Education , 1 credit hour. Lourdes Memorial Hospital Lunch and Learn. Virtual. Jan. 2022.

Platform Presentation: Leppien E . “APhA-ASP Career Conversations Board of Pharmacy Specialties.” American Pharmacists Association Annual Meeting. San Antonio, Tex. Mar. 2022.

Platform Presentation: Leppien E . “NonOpioid Options for Pain Management.” Continuing Education , 1 credit hour. American Pharmacists Association Annual Meeting. San Antonio, Tex. Mar. 2022.

Platform Presentation: Leppien E . “Open Forum: Pharmacists Pain Management and Substance Use Disorder Services.” American Pharmacists Association Annual Meeting. San Antonio, Tex. Mar. 2022.

Sarah Lynch, PharmD

Platform Presentation: Lynch S . “Self Care Hormonal contraceptives? Pharmacy Student Knowledge and Confidence in offering a new community pharmacy service.” American Association of Colleges of Pharmacy Nonprescription Medicines Academy. Cincinnati, Ohio. May 21, 2022.

Melissa Morales, PhD

Platform Presentation: Morales M . “Urine proteomics by mass spectrometry identifies proteins involved in key pathogenic pathways in patients with juvenile dermatomyositis.” Global Conference on Myositis. Prague, Czech Republic. June 6, 2022.

Kanneboyina Nagaraju, PhD

Poster Presentation: Nagaraju K . “Innate and adaptive immune responses to micro dystrophin gene therapy: Safety and efficacy implications for DMD.” Muscular Dystrophy Association Clinical & Scientific Conference. Dallas, Tex. Mar. 15, 2022.

Erin Pauling, PharmD

Platform Presentation: Pauling EE , Cowen N, Hennig K , McGinley JM, Podolak C, Rattinger GB , Rouhana N, Shipe S, Young SR. “Adapting interprofessional simulations during rapid and planned disruptions: lessons from the COVID-19 pandemic.” Lightning Talk at Nexus Summit 2021. Virtual. Sept. 27, 2021.

Platform Presentation: Coleman MD, Pauling EE . “Social Determinants of Health: Impact on Diabetes.” American Pharmacists Association Annual Meeting & Exposition. San Antonio, Tex. Mar. 20, 2022.

Poster Presentation: Felice JA, Gibson EE, Langan AC, Miller ER, Pauling EE . “Determining the Effect of a PharmacyLed Educational Intervention on Provider Knowledge of Using SGLT-2 Inhibitors and GLP-1 Receptor Agonists Outside Type 2 Diabetes Mellitus.” New York State Council of Health-system Pharmacists. Saratoga Springs, N.Y. Apr. 9, 2022.

Gail Rattinger, PhD

Poster Presentation: Murray J, Gonzalez H, Schwartz S, Rattinger GB , Liu Y, Hammond A, Drewel M, Kauzor K, Tschanz J. “Sleep Disturbance and Association with Cognitive and Functional Trajectories in All Cause Dementia: The Cache County Dementia Progression Study.” Alzheimer’s Association International Conference. Denver, Colo. July 26-30, 2021.

Poster Presentation: Drewel M, Gonzalez H, Rattinger GB , Matyi J, Hammond A, Kauzor K, Buhusi M, Tschanz J. “BDNF SNP C270T Modifies the Association between History of Head Injury and Cognitive Status in Older Adults.” Gerontological Society of America Annual Scientific Meeting. Phoenix, Ariz. Nov. 10-14, 2021.

Sara Spencer, PharmD

Poster Presentation: Al-Salameh R, Fama D, Hopkins A, Shah T, Thankachan T, Barbieri M, Spencer SA. “Perceptions of studentpharmacist led COVID point-of-care-testing.” American College of Clinical Pharmacy Annual Meeting. Virtual. Oct. 20, 2021.

Sarah Spinler, PharmD

Platform Presentation: Spinler SA . “Update in the Management of Heart Failure.” Continuing Education, 1 credit hour. Central New York Society of Health-System Pharmacists. Cicero, N.Y. Oct. 12, 2021.

Poster Presentation: Spinler SA, Banghu J, Mahbub K, Marinaro S , Ganesh C. “Emergency Department Medication Discrepancies Identified by Student Pharmacists, and Pharmacy Medication Reconciliation Technicians.” American College of Clinical Pharmacy Annual Meeting. Virtual. Oct. 20, 2021.

Nathan Tumey, PhD

Poster Presentation: Tumey LN . “Design & Optimization of TLR-activating ADCs for Use in Cancer & Infectious Diseases.” World Antibody-drug Conjugate Summit. San Diego, Calif. Oct. 11, 2021.

Poster Presentation: Fang S , Brems B, Olawode E, Tumey LN . “Tumor Targeted Delivery of TLR7 Agonists For The Treatment of Cancer.” Protein Engineering Summit. Boston, Mass. May 2022.

Poster Presentation: Xu F, Ojo V, Leong K, Tumey LN . “Solid-phase Site-Specific Antibody Conjugation Method Leads to ADCs with Retained Efficacy and Improved Stability.” American Chemical Society, Middle Atlantic Regional Meeting. Trenton, N.J. June 2022.

Platform Presentation: Benjamin S, Psaras AM, Leong K, Brooks TA, Tumey LN “Design, Synthesis, and Characterization of MYC-targeting DNAi with Improved Pharmaceutical Properties.” American Chemical Society, Middle Atlantic Regional Meeting. Trenton, N.J. June 2022.

Poster Presentation: DeYoung E, Howe J, Wheeler D , Miller JT, Tumey LN . “Preparation of indoloquinoline TLR7 agonists with improved potency for use in ADC and targeted delivery applications.” American Chemical Society, Middle Atlantic Regional Meeting. Trenton, N.J. June 2022.

Tao Zhang, PhD

Poster Presentation: Holman JM, Ishaq SL, Li Y, Zhang T , Mawe G, Hurd M, Colucci L, Balkan J. “Prevention of Inflammatory Bowel Diseases by Broccoli Sourced and Microbially Produced Bioactives.” American Society for Microbiology Microbe 2022 Conference. Washington, D.C. June 9-13, 2022.

Assistant Professor of Pharmaceutical Sciences Tao Zhang, who joined the School of Pharmacy and Pharmaceutical Sciences in 2022, works in his lab.

School of Pharmacy and Pharmaceutical Sciences Dean Kanneboyina Nagaraju leads a tour of the Pharmacy Building Sept. 27, 2022. From left, New York State Assemblywomen Deborah J. Glick and Donna A. Lupardo, New York State Commissioner of Health Mary T. Bassett and Nagaraju.

SOPPS Publications 2021-2022 (July 1, 2021 to June 30, 2022)

Journal Articles

Ali MAM. The platelet in COVID-19: A critical participant or a bystander? Trends Cardiovasc Med. 2021 Sep 14:S1050-1738(21)00109-2. doi: 10.1016/j.tcm.2021.09.004. Epub ahead of print. PMID: 34534650; PMCID: PMC8438795.

Alosaimy S, Lagnf AM, Morrisette T, Scipione MR, Zhao JJ, Jorgensen SCJ, Mynatt R, Carlson TJ, Jo J, Garey KW, Allen D, DeRonde K, Vega AD, Abbo LM, Venugopalan V, Athans V, Saw S, Claeys KC, Miller M, Molina KC, Veve M, Kufel WD, Amaya L, Yost C, Ortwine J, Davis SL, Rybak MJ. Real-world, Multicenter Experience With MeropenemVaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa. Open Forum Infect Dis. 2021 Jul 14;8(8):ofab371. doi: 10.1093/ofid/ofab371. PMID: 34430671; PMCID: PMC8378588.

Bartholow TG, Sztain T, Young MA, Lee DJ, Davis TD, Abagyan R, Burkart MD. Control of Unsaturation in De Novo Fatty Acid Biosynthesis by FabA. Biochemistry. 2022 March 8;61(7):608-615. doi: 10.1021/acs. biochem.2c00094

Bartholow TG, Sztain T, Young MA, Davis TD, Abagyan R, Burkart MD. Protein-protein interaction based substrate control in the E. coli octanoic acid transferase, LipB. RSC Chem Biol. 2021 Jul 28;2(5):1466-1473. doi: 10.1039/d1cb00125f. PMID: 34704050; PMCID: PMC8495967.

Benny Klimek ME, Vila MC, Edwards K, Boehler J, Novak J, Zhang A, Van der Mulen JH, Tatum K, Quinn J, Fiorillo A, Burki U, Straub V, Lu QL, Hathout Y, van Den Anker J, Partridge TA, Morales M, Hoffman E, Nagaraju K. Effects of Chronic, Maximal Phosphorodiamidate Morpholino Oligomer (PMO) Dosing on Muscle Function and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2021 Sep 18. doi: 10.3233/JND-210701. Epub ahead of print. PMID: 34569970.

Bittel DC, Sreetama SC, Chandra G, Ziegler R, Nagaraju K, Van der Meulen JH, Jaiswal JK. Secreted acid sphingomyelinase as a potential gene therapy for limb girdle muscular dystrophy 2B. J Clin Invest. 2022 Jan 4;132(1):e141295. doi: 10.1172/JCI141295. PMID: 34981776; PMCID: PMC8718136.

Chen C, Seabury RW, Steele JM, Parsels KA, Darko W, Miller CD, Kufel WD. Evaluation of β-lactam therapeutic drug monitoring among US health systems with postgraduate year 2 infectious diseases pharmacy residency programs. Am J Health Syst Pharm. 2022 Apr 19:zxac117. doi: 10.1093/ajhp/zxac117. Epub ahead of print. PMID: 35439284.

Dlott AH, Di Pasqua AJ, Spencer SA Tirbanibulin: Topical Treatment for Actinic Keratosis. Clin Drug Investig. 2021 Sep;41(9):751-755. doi: 10.1007/s40261-02101068-9. Epub 2021 Aug 5. PMID: 34351607.

Echigoya Y, Trieu N, Duddy W, Moulton HM, Yin H, Partridge TA, Hoffman EP, Kornegay JN, Rohret FA, Rogers CS, Yokota T. A

Dystrophin Exon-52 Deleted Miniature Pig Model of Duchenne Muscular Dystrophy and Evaluation of Exon Skipping. Int J Mol Sci. 2021 Dec 2;22(23):13065. doi: 10.3390/ ijms222313065. PMID: 34884867; PMCID: PMC8657897.

Edwards KA. Periplasmic-binding proteinbased biosensors and bioanalytical assay platforms: Advances, considerations, and strategies for optimal utility. Talanta Open. 2021 Aug;3:100038 doi: 10.1016/j. talo.2021.100038

Eidbo SA, Kropp Lopez AK, Hagedorn JD, Mathew V, Kaufman DE, Nichols SD, McCall KL, Piper BJ. Declines and regional variation in opioid distribution by U.S. hospitals. Pain 2022 Jun 1;163(6):1186-1192. doi: 10.1097/j. pain.0000000000002473. Epub 2021 Sep 9. PMID: 34510133.

Failla B, Vest K, Lynch S, Stewart-Lynch A, Bolch CA, White T, French K, Scime G, Griffin BL. Impact of a hormonal contraceptive training program for pharmacists. J Am Pharm Assoc (2003). 2022 Jul-Aug;62(4):1287-1295. e4. doi: 10.1016/j.japh.2022.02.012. Epub 2022 Feb 22. PMID: 35314119.

Gaurkhede SG, Osipitan OO, Dromgoole G, Spencer SA, Pasqua AJD, Deng J. 3D Printing and Dissolution Testing of Novel Capsule Shells for Use in Delivering Acetaminophen. J Pharm Sci. 2021 Aug 29:S0022-3549(21)00463-9. doi: 10.1016/j. xphs.2021.08.030. Epub ahead of print. PMID: 34469748.

Goswami MV, Tawalbeh SM, Canessa EH, Hathout Y. Temporal Proteomic Profiling During Differentiation of Normal and Dystrophin-Deficient Human Muscle Cells. J Neuromuscul Dis. 2021 Sep 30. doi: 10.3233/ JND-210713. Epub ahead of print. PMID: 34602497.

Hassoun N, Friedman J, Cosler LE. A Framework for Assessing the Impact of Disease Treatment. Trop Med Int Health. 2021 Dec 4. doi: 10.1111/tmi.13706. Epub ahead of print. PMID: 34862707.

Hu M, Bi H, Moffat D, Blystone M, DeCostanza P, Alayi T, Ye K, Hathout Y, Jin S. Proteomic and Bioinformatic Analysis of Decellularized Pancreatic Extracellular Matrices. Molecules 2021 Nov 8;26(21):6740. doi: 10.3390/ molecules26216740. PMID: 34771149; PMCID: PMC8588251.

Jaiswal J, Nagaraju K, Morgan J. Terence A Partridge: A career dedicated to pursuit of curiosity, mentorship, and secrets of skeletal muscle stem cells. J Neuromuscul Dis. 2021 Nov 14. doi: 10.3233/JND-219010. Epub ahead of print. PMID: 34806614.

Kelley EF, Cross TJ, McDonald CM, Hoffman EP, Bello L. Influence of β2 adrenergic receptor genotype on longitudinal measures of forced vital capacity in patients with Duchenne muscular dystrophy. Neuromuscul Disord. 2022 Jan 4:S0960-8966(21)00740-9. doi: 10.1016/j.nmd.2021.12.006. Epub ahead of print. PMID: 35115229.

Klosko RC, Saphire ML. Topical Morphine Gel as a Systemic Opioid Sparing Technique. J Pain Palliat Care Pharmacother. 2022 Jun 9:17. doi: 10.1080/15360288.2022.2084488. Epub ahead of print. PMID: 35678475.

Kufel WD, Asiago-Reddy EA, Parsels KA, Sanyal S, Coyne JL. Successful treatment with secnidazole for trichomoniasis in the setting of metronidazole hypersensitivity. Int J STD AIDS. 2021 Aug 15:9564624211034974. doi: 10.1177/09564624211034974. Epub ahead of print. PMID: 34392726.

Kufel WD, Blaine BE, Ruehl R, Avery LM. Instruction and Simulation to Improve Pharmacy Students’ Knowledge and Confidence Regarding Assessment of Penicillin Allergies. Am J Pharm Educ. 2022 Mar;86(3):8688. doi: 10.5688/ajpe8688. Epub 2021 Jul 22. PMID: 34301577.

Kufel WD, Mastro KA, Steele JM, Wang D, Riddell SW, Paolino KM, Thomas SJ. Impact of a pharmacist-facilitated, evidence-based bundle initiative on Staphylococcus aureus bacteremia management. Diagn Microbiol Infect Dis. 2021 Sep 4;101(4):115535. doi: 10.1016/j.diagmicrobio.2021.115535. Epub ahead of print. PMID: 34634714.

Li N, Parkes JE, Spathis R, Morales M, Mcdonald J, Kendra RM, Ott EM, Brown KJ, Lawlor M, Nagaraju K. The Effect of Immunomodulatory Treatments on AntiDystrophin Immune Response After AAV Gene Therapy in Dystrophin Deficient mdx Mice. J Neuromuscul Dis. 2021 Sep 23. doi: 10.3233/JND-210706. Epub ahead of print. PMID: 34569971.

Mah JK, Clemens PR, Guglieri M, Smith EC, Finkel RS, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, McDonald CM, Damsker JM, Schwartz BD, Mengle-Gaw LJ, Jackowski S, Stimpson G, Ridout DA, AyyarGupta V, Baranello G, Manzur AY, Muntoni F, Gordish-Dressman H, Leinonen M, Ward LM, Hoffman EP, Dang UJ; NorthStar UK Network and CINRG DNHS Investigators. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial. JAMA Netw Open. 2022 Jan 4;5(1):e2144178. doi: 10.1001/jamanetworkopen.2021.44178. PMID: 35076703; PMCID: PMC8790668.

Mamsa H, Stark RL, Shin KM, Beedle AM, Crosbie RH. Sarcospan increases laminin binding capacity of α-dystroglycan to ameliorate DMD independent of Galgt2. Hum Mol Genet. 2021 Sep 28:ddab276. doi: 10.1093/ hmg/ddab276. Epub ahead of print. PMID: 34581784.

Nagaraju K, Morales M. Targeting necroptosis for the treatment of myositis. Nat Rev Rheumatol. 2022 Jun;18(6):307308. doi: 10.1038/s41584-022-00775-7. PMID: 35388209.

Novak JS, Spathis R, Dang UJ, Fiorillo AA, Hindupur R, Tully CB, Mázala DAG, Canessa E, Brown KJ, Partridge TA, Hathout Y, Nagaraju K. Interrogation of Dystrophin and Dystroglycan Complex Protein Turnover After Exon Skipping Therapy. J Neuromuscul Dis 2021 Sep 23. doi: 10.3233/JND-210696. Epub ahead of print. PMID: 34569969.

Ogundele M, Zhang JS, Goswami MV, Barbieri ML, Dang UJ, Novak JS, Hoffman EP, Nagaraju K, Cinrg-Dnhs Investigators, Hathout Y. Validation of Chemokine Biomarkers in Duchenne Muscular Dystrophy. Life (Basel). 2021 Aug 13;11(8):827. doi: 10.3390/ life11080827. PMID: 34440571; PMCID: PMC8401931.

Parsels KA, Kufel WD, Burgess J, Seabury RW, Mahapatra R, Miller CD, Steele JM. Hospital Discharge: An Opportune Time for Antimicrobial Stewardship. Ann Pharmacother 2021 Nov 5:10600280211052677. doi: 10.1177/10600280211052677. Epub ahead of print. PMID: 34738475.

Patel JJ, Volino LR, Cosler LE, Wang X, KaneGill SL, Toscani M, Barone JA. Opioid abuse risk among student pharmacists. J Opioid Manag. 2022 Mar-Apr;18(2):161-166. doi: 10.5055/jom.2022.0706. PMID: 35476885.

Pauling EE, Nguyen TT, Valentino AS, Ducker Coleman M. Using the Pharmacists’ Patient Care Process to address social determinants of health in patients with diabetes. J Am Pharm Assoc (2003). 2022 Jan 19:S1544-3191(22)00008-5. doi: 10.1016/j.japh.2022.01.008. Epub ahead of print. PMID: 35144864.

Psaras AM, Chang KT, Hao T, Brooks TA. Targeted Downregulation of MYC through G-quadruplex Stabilization by DNAi. Molecules. 2021 Sep 13;26(18):5542. doi: 10.3390/molecules26185542. PMID: 34577013; PMCID: PMC8464964.

Psaras AM, Miller J, Tumey LN, Brooks TA Anticancer activitiy of indolo 2,3-c quinoline

stabilization of the KRAS promoter G4(mid) structure. Cancer Research. 2021 Jul;81(13). doi: 10.1158/1538-7445.AM2021-1246.

Psaras AM, Valiuska S, Noé V, Ciudad CJ, Brooks TA. Targeting KRAS Regulation with PolyPurine Reverse Hoogsteen Oligonucleotides. Int J Mol Sci. 2022 Feb 14;23(4):2097. doi: 10.3390/ijms23042097. PMID: 35216221; PMCID: PMC8876201.

Rebold N, Morrisette T, Lagnf AM, Alosaimy S, Holger D, Barber K, Justo JA, Antosz K, Carlson TJ, Frens JJ, Biagi M, Kufel WD, Moore WJ, Mercuro N, Raux BR, Rybak MJ. Early Multicenter Experience With ImipenemCilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections. Open Forum Infect Dis. 2021 Dec 9;8(12):ofab554. doi: 10.1093/ ofid/ofab554. PMID: 34901302; PMCID: PMC8661073.

Roy R, Soldin SJ, Stolze B, Barbieri M, Tawalbeh SM, Rouhana N, Fronczek AE, Nagaraju K, van den Anker J, Dang UJ, Hoffman EP. Acute serum protein and cytokine response of single dose of prednisone in adult volunteers. Steroids. 2022 Feb;178:108953. doi: 10.1016/j.steroids.2021.108953. Epub 2022 Jan 10. PMID: 35026285.

Sabbatini D, Fusto A, Vianello S, Villa M, Janik J, D’Angelo G, Diella E, Magri F, Comi GP, Panicucci C, Bruno C, D’Amico A, Bertini E, Astrea G, Battini R, Politano L, Masson R, Baranello G, Previtali SC, Messina S, Vita G, Berardinelli A, Mongini T, Pini A, Pane M, Mercuri E, Hoffman EP, Morgenroth L, Gordish-Dressman H, Duong T, McDonald

CM, Bello L, Pegoraro E. Genetic modifiers of upper limb function in Duchenne muscular dystrophy. J Neurol. 2022 May 5. doi: 10.1007/ s00415-022-11133-8. Epub ahead of print. PMID: 35513612.

Siddiqui MZ, Piserchio JP, Patel M, Park J, Foster ML, Desrosiers CE, Herbert J, Nichols SD, McCall KL, Piper BJ. Examination of multiple drug arrests reported to the Maine Diversion Alert Program. Forensic Sci Med Pathol. 2022 Jun;18(2):133-140. doi: 10.1007/ s12024-021-00454-1. Epub 2022 Jan 30. PMID: 35094290.

Smith HR, Canessa EH, Roy R, Spathis R, Pour MS, Hathout Y. A single tick screening for infectious pathogens using targeted mass spectrometry. Anal Bioanal Chem. 2022 May;414(13):3791-3802. doi: 10.1007/s00216022-04054-y. Epub 2022 Apr 13. PMID: 35416505.

Sun M, Dang UJ, Yuan Y, Psaras AM, Osipitan O, Brooks TA, Lu F, Di Pasqua AJ. Optimization of DOTAP/chol Cationic Lipid Nanoparticles for mRNA, pDNA, and Oligonucleotide Delivery. AAPS PharmSciTech 2022 May 9;23(5):135. doi: 10.1208/s12249022-02294-w. PMID: 35534697; PMCID: PMC9084260.

Tavasoli M, Feridooni T, Feridooni H, Sokolenko S, Mishra A, Lefsay A, Srinivassane S, Reid SA, Rowsell J, Praest M, MacKinnon A, Mammoliti M, Maloney AA, Moraca M, Uaesoontrachoon K, Nagaraju K, Hoffman EP, Pasumarthi KBS, McMaster CR. A mouse model of inherited choline kinase β-deficiency

presents with specific cardiac abnormalities and a predisposition to arrhythmia. J Biol Chem. 2022 Feb 10:101716. doi: 10.1016/j. jbc.2022.101716. Epub ahead of print. PMID: 35151687.

Tavasoli M, Lahire S, Sokolenko S, Novorolsky R, Reid SA, Lefsay A, Otley MOC, Uaesoontrachoon K, Rowsell J, Srinivassane S, Praest M, MacKinnon A, Mammoliti MS, Maloney AA, Moraca M, Pedro FernandezMurray J, McKenna M, Sinal CJ, Nagaraju K, Robertson GS, Hoffman EP, McMaster CR. Mechanism of action and therapeutic route for a muscular dystrophy caused by a genetic defect in lipid metabolism. Nat Commun. 2022 Mar 23;13(1):1559. doi: 10.1038/s41467-02229270-z. PMID: 35322809.

Valentino AS, Nguyen TT, Pauling EE, Coleman MD, Lee C, Araojo R. Collaborating with pharmacists to advance health equity for patients with diabetes through communication. J Am Pharm Assoc (2003). 2022 Jan 19:S1544-3191(22)00009-7. doi: 10.1016/j.japh.2022.01.009. Epub ahead of print. PMID: 35168875.

Xiao J, Shi J, Thompson BR, Smith DE, Zhang T, Zhu HJ. Physiologically-Based Pharmacokinetic Modeling to Predict Methylphenidate Exposure Affected by Interplay Among Carboxylesterase 1 Pharmacogenetics, DrugDrug Interactions, and Sex. J Pharm Sci. 2022 May 6:S0022-3549(22)00190-3. doi: 10.1016/j. xphs.2022.04.019. Epub ahead of print. PMID: 35526575.

Yang H, Xue I, Gu Q, Zou P, Zhang T, Lu Y, Fisher J, Tran D. Developing an In Vitro to In Vivo Extrapolation (IVIVE) Model to Predict Human Milk-to-Plasma Drug Concentration Ratios. Mol Pharm. 2022 Jul 4;19(7):25062517. doi: 10.1021/acs.molpharmaceut.2c00193. Epub 2022 Jun 8. PMID: 35675046.

Zhang T, Applebee Z, Zou P, Wang Z, Diaz ES, Li Y. An in vitro human mammary epithelial cell permeability assay to assess drug secretion into breast milk. Int J Pharm X. 2022 Jun 22;4:100122. doi: 10.1016/j. ijpx.2022.100122. PMID: 35789754; PMCID: PMC9249612.

Book Contributions

Kufel WD. Interactive Case: Antimicrobial Pharmacokinetic and Pharmacodynamic Considerations. Ambulatory Care SelfAssessment Program (ACSAP). 2022 Book 2. Infectious Disease in Ambulatory Care. Lenexa (KS): American College of Clinical Pharmacy (ACCP);2022. p. 162-171.

Spinler SA. Oral anticoagulation therapy. In: Levine GN, editors. Cardiology secrets. 6th ed. Philadelphia (PA): Elsevier; 2021. p. 548-562.

Spinler SA, Gulseth MP. Prevention and treatment of COVID-19-related thrombosis. In: Sanoski CA, Witt DM, eds. Pharmacotherapy Self-Assessment Program (PSAP), 2022 Book 2. Current Issues in Pharmacotherapy. Lenexa (KS): American College of Clinical Pharmacy (ACCP);2022. p. 59-84.

Spinler SA, Carlson L. Thromboembolic Disorders. In: Arcangelo VP, Peterson AM, Wilbur V, King TF, editors.

Pharmacotherapeutics for Advanced Practice: A Practical Approach. 5th ed. Philadelphia (PA): Wolters Kluwer;2021. p. 49.

Rogers KC, Spinler SA. Acute coronary syndromes. In: Chisholm-Burns MA, Schwinghammer TL, Malone PM, Kolesar JM, Lee KC, Bookstaver PB, editors. Pharmacotherapy principles and practice. 6th ed. New York (NY): McGraw-Hill;2022. p. 157-184.

Miller JT, Tumey LN. ADC Linker Strategies for the Release of Alcohol-Containing Payloads. In: van Delft F, Lambert JM, editors. Chemical Linkers in Antibody-Drug Conjugates (ADCs) Royal Society of Chemistry. Croydon (UK): CPI Group (UK) Ltd; 2021, p. 232-262.

Patent application

Tumey LN, Olawode E. “Targeted-Delivery of TLR7/8 Agonists for the Treatment of Cancer and/or Infectious Diseases.” WO2022187809. Filed March 1, 2022.

Ryan Kendra, left, Mi Lei, center, and Brett Krummenacker, all P3 students, discuss a patient’s history as they work together in the Skills Lab to determine the best medication plan for the patient.

Our funding 2021-2022

Total research expenditures: $966,759

Aaron Beedle

$15,612 Total Expenditures

SBIR Phasel: Building an Evidentiary Case for Circulating GHBP as a Biomarker for Drug Associated Stunting of Growth

ReveraGen Biopharma Incorporated

Tracy Brooks

$111,827 Total Expenditures

$55,913 Tracy Brooks, $55,913 L. Nathan Tumey

Synthesis and Optimization of antibody: DNAi conjugates targeting the MYC G4

National Cancer Institute

Tony Davis

$91,936 Total Expenditures

Interrogation of Microbial Natural Product mEthyltransferases

National Institute of General Medical Sciences

Katie Edwards

$5,767 Total Expenditures

$2,769

Bridging pharmacodynamic biomarkers to clinical outcomes in pediatric inflammatory diseases

Children’s Research Institute $2,999

Thiaminase analysis in Asian Carp RADii Solutions

William Eggleston $357 Total Expenditures

Evaluating the Impact of an at Home Medication Disposal System on Safe Medication Disposal

NYS Chapter of American College of Clinical Pharmacy

Yetrib Hathout

$146,276 Total Expenditures

$88,220

Bridging Pharmacodynamic Biomarkers to Clinical Outcomes in Pediatric Inflammatory Diseases

Children’s Research Institute

$31,927

R61/R33 Resubmission (Biomarker Signatures for Duchenne Muscular Dystrophy)

National Inst of Neurological Disorders & Stroke

$5,476

A biomarker and patient-reported outcomes study in Becker muscular dystrophy patients

ReveraGen Biopharma Incorporated

$15,625

Generation of Stable Isotope Labeled Dystrophin Through Culturing of Immortalized Human Muscle Cells

Vertex Pharmaceuticals Incorporated

$5,029

Clinical Utility of Serum Protein Biomarkers in Very Young Duchenne Muscular Dystrophy Boys

US Army Medical Research Acquisition Activity

Wesley Kufel

$31,351 Total Expenditures

$30,558

A quasi-experimental study to evaluate the use of empiric antibiotic order sets for common infectious states

Merck Sharp and Dohme Corporation $793

Impact of Vancomycin Plus Ceftaroline Combination Therapy for Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia

NYS Chapter of American College of Clinical Pharmacy

Amanda Mogul

$1,701 Total Expenditures

Identifying Patients Inappropriately Prescribed Aspirin for Primary Prevention in a Primary Care Clinic

NYS Council of Health-system Pharmacists

Kanneboyina Nagaraju

$182,732 Total Expenditures $39,842

Testing and screening potential compounds for efficacy in a mouse model of myositis and the effect of Type 1 Interferon on muscle function and weakness in myositis

CURE JM Foundation $10,014

Unrestricted Research: DB Therapeutics in the area of radiotherapeutic bandage DB Therapeutics Incorporated $11,826

Immune response to dystrophin after Etiplerson treatment in Duchenne Muscular Dystrophy Children

Foundation to Eradicate Duchenne

$3,807: $1,904 Melissa Morales, $1,904 Kanneboyina Nagaraju

Improving muscle weakness by blocking the Interferon signature with anti-viral proteins Myositis Association

$25,516

Effect of Immunomodulatory Treatments on Immune Response After Gene Correction in DMD

Parent Project for Muscular Dystrophy Research Inc $91,727

Targeting the innate immune system to block acute inflammatory and chronic immune responses to transgene and AAV vector in DMD

Parent Project for Muscular Dystrophy Research Inc

L. Nathan Tumey

$376,060 Total Expenditures

$141,503

Cell-specific blockage of TLR activation: A new strategy for addressing inflammatory disorders

National Institute of Allergy & Infectious Disease $50,791

“Molecular whack-a-mole”: Targeting Transmembrane- TNFa for the Delivery of Anti-Inflammatory Drugs

National Institute of Allergy & Infectious Disease

$144,997

Exploiting the Hydrophobic Glycosyl Pocket of lgG1 for Imaging and Drug Delivery Applications

National Institute of General Medical Sciences

$34,499: $17,250 Tracy Brooks, $17,250 L. Nathan Tumey

Legumain to the rescue: A new ADC linker strategy to address the limitations of cathepsin cleavage

National Institute of General Medical Sciences $4,270

Cell Lysates from Synthis Synthis Therapeutics Tao Zhang $3,140 Total Expenditures

To measure permeability of BCRP drug substrates and establish mechanistic IVIVE and PBPK model to predict milk drug transfer

US Food and Drug Administration

MASTER AND PHD PROGRAMS IN PHARMACEUTICAL SCIENCES UNDERWAY

Hands-on learning develops new researchers

When Binghamton University’s School of Pharmacy and Pharmaceutical Sciences (SOPPS) was established in 2017, the only degree program it offered was the Doctor of Pharmacy. But the vision was to add master’s and doctoral programs in pharmaceutical sciences, and those programs launched in fall 2022.

“Launching these programs was a priority for SOPPS,” said Dean Kanneboyina Nagarau. “The MS and PhD programs in pharmaceutical sciences are key to the research mission of both SOPPS and Binghamton University.”

The approval process for advanced-degree programs is demanding. Not only do they require campus approval, but they must also be approved by the New York State Education Department and SUNY system administration.

“We started at pretty much the same time we enrolled our first PharmD class,” says Nathan Tumey, associate professor of pharmaceutical

sciences and assistant graduate director. “About five years ago we started putting all of the required documents for the Master of Science (MS) and PhD programs together in earnest.”

Now with 15 students between the two programs — eight MS and seven PhD students — the first-year targets were met, says Yetrib Hathout, professor of pharmaceutical sciences and graduate director. “We want to keep our classes small, especially for the master’s students, because they have hands-on classes and labs and this kind of one-on-one work will help get them job-ready.”

Madison King came all the way from North Dakota to start her PhD program in pharmaceutical sciences at Binghamton. It might be a bit warmer here in the winter than her 20 degrees below zero native state, but what attracted her to Binghamton is the cutting-edge equipment, the faculty and the building.

“I was looking at programs online and saw you were just starting your first batch of students,

and that’s interesting to me,” King says. “The way I designed my undergraduate degree, I did a lot of pharmaceutical sciences lab research, so I knew what I was getting into. Then I came out here and met with a lot of faculty and thought, ‘This is really awesome.’ They all emphasized that they care about students and I didn’t get that anywhere else — and the building is new so the air conditioning won’t go out and let my cells get contaminated!”

King hopes to one day work in gene therapy. “I have a family member who has a genetic disease and she was put on a gene therapy and it completely changed her life,” King says. “I want to be able to give that to other people. That’s my ultimate goal.”

MS student Michael Coyle also has a specific goal. As an undergraduate at Binghamton, he began working in the lab of Christopher Bishop, professor of psychology. Following his graduation in 2019 with a bachelor’s degree in integrative neuroscience, Coyle continued working in Bishop’s

Madison King

lab, researching potential therapeutics to ease Parkinson’s disease symptoms.

Bishop established a company, Neuralina Therapeutics, and has developed a candidate drug for Parkinson’s disease. Coyle chose the path to an MS to become more educated about the later side of drug development — something that will help him as he continues working with Bishop and Neuralina.

Already, Coyle is putting what he is learning in the MS program to use in the Bishop lab. “Everything we’re studying in class is immediately relating to the drugs we’re working on or the experiments we need to do,” he said. ”Everything we have discussed I’ve tagged to the drugs we’re working on to get a better idea of exactly what they are.”

The hands-on lab experience Coyle and King are experiencing differentiates Binghamton’s program from those at other schools, Tumey says. “A core component of the MS is a class designed to provide hands-on experience in instrumental analysis. Students will learn how to use the instrumentation, rather than just learn about it in the classroom.”

Having undergraduate research experience at Binghamton has also helped feed the programs. There are currently three master’s students, including Coyle, and one PhD student who fall into this category. “Exposing students to research at the undergraduate level is an important step in their career path,” Hathout said. “Undergraduates sometimes don’t know what they want to do, so when we show them that this is an interesting

Michael Coyle

area of research and a viable career path, we feel really proud of that.”

And what Coyle is learning now will set him up for career success, said Tumey. “Within the pharmaceutical industry there are a lot of openings for MS degree students. The job market is pretty hot for people coming in…. most of those with bachelor’s don’t have a lot of hands-on experience but our MS students will have this instrumental analysis course along with a research-based internship so they will come out with some practical skills that are in high demand in pharmaceutical and biotechnology companies.

Following their third rotation, they are matched with an advisor that is the best fit based on feedback from both the students and the advisors.

“One reason we think this process is attractive for students is that choosing a PhD advisor is one of the most monumental decisions students will make in their entire life,” Tumey says. “A good match can launch a career and fuel years of exciting research. But a poor match can make for a very difficult four years of life.”

SOME CAREER POSSIBILITIES FOR MS AND PHD STUDENTS

•

•

•

•

•

•

•

•

“And, of course, our PhD students will also get plenty of hands-on experience,” he adds, beginning with rotations through three different labs where they learn about a particular faculty member’s research and the technology used. “The rotation experience is a bit like a dating relationship — the professor and student are looking for a good fit before making a 4-year commitment to an advisor.”

“And we’re here to mentor students,” he added. “We’re eager to mentor because that’s how we do what we love. PhD students are the engine that keeps scientific enterprise going. Lab rotations increase faculty workload, but the outcome is worth the investment.”

Another distinguishing part of the MS and PhD programs is flexibility between labs, says Hathout. “When a student works in one of our labs, there is no border between the different labs. A student in Tumey’s lab can learn from others, and that’s very important. There are no silos. We don’t have any borders and students can be mentored by several advisors.”

The first two years of the PhD program is when the students are taught to fly on their own, Hathout explained. “Then they start thinking and designing experiments and reading the literature. We try to teach them to critically think and become independent researchers.”

One additional thing that sets this department apart from other pharmaceutical sciences programs is some of the industrial connections and collaborations that we have, Tumey said.

“There are multiple professors here who came out of the pharmaceutical industry and are active consultants at companies, members of scientific advisory boards or are even involved in managing companies,” he said. “That’s useful for two reasons: First, it keeps what we are teaching relevant and practical. Secondly, since many of us are actively connected to the private sector, we have multitudes of connections that can assist with internships, jobs and funding. In fact, some of our courses bring in guest lecturers from these companies to teach various aspects of drug discovery and regulatory affairs.”

Placement success is already a hallmark for students who have conducted research with SOPPS faculty, and that success is expected to continue, whether for internships or jobs. Graduates coming out of the Binghamton pharmsci labs have landed jobs at companies including Regeneron, Genmab and Nektar Therapeutics.

“One additional feature of our program is its close affiliation with the PharmD program. Because of this relationship, our students are exposed to clinical faculty and they serve as teaching assistants in pharmacy classes. This means that they are seeing the continuum from drug discovery all the way to patient care,” Tumey says, which can be attractive to agencies in both the public and private sector looking to hire. “Many of these organizations hire people with the sort of expertise we are developing in these students. Bachelor’s degrees won’t get you that. A specialized pharmaceutical background is essential.”

School of Pharmacy and Pharmaceutical Sciences

PO Box 6000 Binghamton, NY 13902-6000 96 Corliss Ave. Johnson CIty, N.Y. 13790 binghamton.edu/pharmacy-and-pharmaceutical-sciences